Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors

scientific article

Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1541-7786.MCR-08-0067
P698PubMed publication ID18644978
P5875ResearchGate publication ID51418907

P50authorOlivier HermineQ28322530
Patrice DubreuilQ30089953
P2093author name stringYing Yang
Alain Moussy
Jean-Pierre Kinet
Phillip S Leventhal
Sébastien Letard
Katia Hanssens
Fabienne Palmérini
Stéphanie Guéry
P2860cites workEstablishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectorsQ42805800
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectmast cellQ191989
P304page(s)1137-1145
P577publication date2008-07-01
P1433published inMolecular Cancer ResearchQ2751014
P1476titleGain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors
P478volume6

Reverse relations

cites work (P2860)
Q35596167A point mutation in the extracellular domain of KIT promotes tumorigenesis of mast cells via ligand-independent auto-dimerization
Q37333653A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs
Q38249785A retrospective review of treatment and response of high-risk mast cell tumours in dogs
Q64063417A synonymous germline variant in a gene encoding a cell adhesion molecule is associated with cutaneous mast cell tumour development in Labrador and Golden Retrievers
Q39686603Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines
Q34674644Analysis of c-KIT exon 11 mutations in canine gastrointestinal stromal tumours
Q38877571Application of post-genomic techniques in dog cancer research.
Q50025491Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features
Q35017911Beyond H&E: integration of nucleic acid-based analyses into diagnostic pathology
Q39560865Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses
Q38506396C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic.
Q52889038CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells.
Q90211834Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning
Q38884478Canine cutaneous mast cell tumors: A combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection
Q54544577Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
Q97524610Canine mast cell tumors: diagnosis, treatment, and prognosis
Q54626445Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.
Q92151739Companion Animals as Models for Inhibition of STAT3 and STAT5
Q57174064Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms
Q36873386Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline
Q36615998Cutaneous mastocytosis with a mutation in the juxtamembrane domain of c-kit in a young laboratory beagle dog.
Q21560915Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy
Q54208733Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma.
Q33726782Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.
Q52888331Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours.
Q37154730Digital pathology and image analysis augment biospecimen annotation and biobank quality assurance harmonization
Q28085473Dysregulation of tyrosine kinases and use of imatinib in small animal practice
Q38033673European consensus document on mast cell tumours in dogs and cats
Q38376182Expression of Phosphorylated KIT in Canine Mast Cell Tumor.
Q39698999Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas
Q37696540Gene expression of growth factors and growth factor receptors for potential targeted therapy of canine hepatocellular carcinoma.
Q37095268Generation and characterization of novel canine malignant mast cell line CL1.
Q35847076Genome-Wide Association Study of Golden Retrievers Identifies Germ-Line Risk Factors Predisposing to Mast Cell Tumours
Q40433142Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade
Q44695820Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours
Q64232058Heteroplasmic Mutations and Polymorphisms in the Gene of Mitochondrial DNA in Canine Mast Cell Tumours
Q48120081IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.
Q40159924Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor
Q36078994Identification of the two KIT isoforms and their expression status in canine hemangiosarcomas
Q54590837Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
Q34670665Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
Q33780403Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11.
Q43537487Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation
Q38798420KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
Q53084383Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.
Q55043104Masitinib monotherapy in canine epitheliotropic lymphoma.
Q51544382Mast Cell Tumors in a Llama (Lama Glama)
Q54530545Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Q35839839Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors
Q39348704NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.
Q55366271Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study).
Q35092066Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis
Q93010074Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours
Q47742852Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours
Q54452285Prognostic significance of Kit receptor tyrosine kinase dysregulations in feline cutaneous mast cell tumors.
Q54315490RETRACTED: Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology.
Q58921202Rapid Evaluation of Mutant Exon-11 inc-kitin a Recurrent MCT Case Using CD117 Immunocytofluorescence, FACS-Cell Sorting, and PCR
Q53313967Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors.
Q54613659Safety of masitinib mesylate in healthy cats.
Q54296742Sensitive detection of the c-KIT c.1430G>T mutation by mutant-specific polymerase chain reaction in feline mast cell tumours.
Q35217229Sequencing and G-quadruplex folding of the canine proto-oncogene KIT promoter region: might dog be used as a model for human disease?
Q55066232Small molecule kinase inhibitors in veterinary oncology.
Q57027822Structural and copy number chromosome abnormalities in canine cutaneous mast cell tumours
Q51769124Targeted knockdown of canine KIT (stem cell factor receptor) using RNA interference.
Q36020577Targeting membrane proteins for antibody discovery using phage display.
Q38255489The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells
Q89786520The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs
Q51011082The use of COLD-PCR, DHPLC and GeneScanning for the highly sensitive detection of c-KIT somatic mutations in canine mast cell tumours.
Q43727603The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours.
Q51657471Transcriptional profiling of canine mast cell tumors: Searching for candidate targets and prognostic markers.
Q34322014Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes
Q64930574Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.
Q54322229c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.
Q48196847c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Q33677797c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies.
Q44195615p62/Sequestosome-1: Mapping Sites of Protein-Handling Stress in Canine Cutaneous Mast Cell Tumors

Search more.